DataString Consulting Company Logo
DataString Consulting Company Logo
Golimumab Market
Home»Top Market Reports»Golimumab Market

Golimumab Market

Author: Debadatta Patel - Senior Consultant, Report ID - DS1802080, Published - March 2025

Segmented in Drug Form (Injection, Infusion), Treatment Application (Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Others), Distribution Channel, End-User and Regions - Global Industry Analysis, Size, Share, Trends, and Forecast 2024 – 2034

Share this report:

Global Golimumab Market Outlook

The market, for Golimumab was estimated at $16.8 billion in 2024; and it is anticipated to increase to $21.6 billion by 2030 with projections indicating a growth to around $26.7 billion by 2035. This expansion represents a compound annual growth rate (CAGR) of 4.3% over the forecast period. The substantial expansion of the golimumab market can be credited to its role in the healthcare sector and specifically in rheumatology practice areas. Its increasing popularity stems from its ability to advance treatment methodologies with proven effectiveness and regulatory backing. The continued relevance of golimumab signifies not only a rise in autoimmune conditions but also the ongoing quest, for better and enduring treatment options.


A tier human made monoclonal antibody known as Golimumab has become a key player in various medical procedures that provide new hope to patients dealing with autoimmune disorders. The FDA approved biologic has gained recognition for its diverse uses in treating conditions such as rheumatoid arthritis psoriatic arthritis ankylosing spondylitis and ulcerative colitis among others. Recent developments in medicine and the increasing popularity of biologics have contributed to its growing demand thus solidifying Golimumabs significant role, in the field of medicine.


Market Size Forecast & Key Insights

2019
$16.8B2024
2029
$25.6B2034

Absolute Growth Opportunity = $8.8B

The Golimumab market is projected to grow from $16.8 billion in 2024 to $25.6 billion in 2034. This represents a CAGR of 4.3%, reflecting rising demand across Rheumatoid Arthritis Treatment, Ankylosing Spondylitis Therapy and Psoriatic Arthritis Management.

The Golimumab market is set to add $8.8 billion between 2024 and 2034, with manufacturer targeting Psoriatic Arthritis & Ankylosing Spondylitis Treatment Application projected to gain a larger market share.

With Rising prevalence of autoimmune disorders, and Advancements in biologics, Golimumab market to expand 52% between 2024 and 2034.

Opportunities in the Golimumab Market

Strategic Collaborations within the Biotech industry

When it comes to treating diseases with golimumab it could be beneficial to form partnerships, with biotech firms specializing in personalized medicine and genomics for new opportunities and advancements.

Expansion into Emerging Markets and Technological Innovations in Drug Administration

As someone experienced in market research analysis I have found a potential for golimumab in emerging markets with rising cases of rheumatoid arthritis. These regions are experiencing growth yet are frequently overlooked in healthcare strategies. Given golimumabs success in treating arthritis venturing into markets, like China, India and Brazil could lead to considerable expansion opportunities.

Market trends show a keen interest in non-invasive methods for drug administration. Golimumab, currently administered via subcutaneous injections, could potentially embrace this trend through technological innovation. Developing a new administration method that makes use of advances in transdermal drug delivery could not only meet customer needs for comfort but also position golimumab at the forefront of its market segment.

Growth Opportunities in North America and Europe

Europe Outlook

Europe has a established healthcare system that offers great potential for expanding the use of golimumab medication. The aging population and high rates of auto diseases in this region highlight the need for effective treatments like golimumab. Additionally; the strong emphasis placed by healthcare professionals and solid healthcare facilities play a role in promoting the growth of golimumab. In the European Union countries such as Germany; France; and the United Kingdom stand out as regions for golimumab due, to their advanced clinical expertise. Established pharmaceutical companies contribute to the environment within the golimumab market throughout Europe.

North America Outlook

North America is widely recognized as a hub for advancements and breakthroughs in healthcare technology innovation with golimumab being a key player in the market here. Patients are increasingly informed about the benefits of golimumab well as its wide range of therapeutic uses which contributes to its popularity in this region. The healthcare sector in North America benefits from substantial investments from both private and public sectors along with a regulatory framework that supports the growth and adoption of treatments like golimumab. Golimumab has shown growth potential in various region's such as arthritis and dermatology, within North America. The strong influence of leading biotechnology companies and the competitive environment, for innovative and impactful biological products are key elements influencing the golimumab market in North America.

North America Outlook

North America is widely recognized as a hub for advancements and breakthroughs in healthcare technology innovation with golimumab being a key player in the market here. Patients are increasingly informed about the benefits of golimumab well as its wide range of therapeutic uses which contributes to its popularity in this region. The healthcare sector in North America benefits from substantial investments from both private and public sectors along with a regulatory framework that supports the growth and adoption of treatments like golimumab. Golimumab has shown growth potential in various region's such as arthritis and dermatology, within North America. The strong influence of leading biotechnology companies and the competitive environment, for innovative and impactful biological products are key elements influencing the golimumab market in North America.

Europe Outlook

Europe has a established healthcare system that offers great potential for expanding the use of golimumab medication. The aging population and high rates of auto diseases in this region highlight the need for effective treatments like golimumab. Additionally; the strong emphasis placed by healthcare professionals and solid healthcare facilities play a role in promoting the growth of golimumab. In the European Union countries such as Germany; France; and the United Kingdom stand out as regions for golimumab due, to their advanced clinical expertise. Established pharmaceutical companies contribute to the environment within the golimumab market throughout Europe.

Growth Opportunities in North America and Europe

Established and Emerging Market's Growth Trend 2025–2034

1

Major Markets : United States, Germany, France, Japan, United Kingdom are expected to grow at 3.0% to 4.0% CAGR

2

Emerging Markets : Brazil, Russia, India are expected to grow at 4.7% to 6.0% CAGR

Market Analysis Chart

The need for golimumab has surged in the pharmaceutical market as a therapeutic antibody treatment option has gained traction in treating various autoimmune conditions like rheumatoid arthritis and psoriatic arthritis, among others.

Recent Developments and Technological Advancement

December 2024

Johnson & Johnsons biopharmaceutical sector revealed plans to broaden the availability of golimumab by introducing Simponi to the Asian Pacific market.

October 2024

Med PACTs latest report forecasts the expansion of the golimumab market with a notable uptick in demand expected due to the global surge, in arthritis and other associated ailments.

August 2024

Merck Pharmaceuticals revealed a collaboration, with Biocon Biologics aiming to concentrate on advancing and marketing their products based on golimumab.

there have been advancements in the utilization of golimumab for treating autoimmune disorders such as rheumatoid arthritis and psoriatic arthritis as well as ankylosing spondylitis thanks to improvements, in technology and healthcare practices.

Impact of Industry Transitions on the Golimumab Market

As a core segment of the Pharmaceutical industry, the Golimumab market develops in line with broader industry shifts. Over recent years, transitions such as Embracing Biosimilars and Technological Innovation in Drug Administration have redefined priorities across the Pharmaceutical sector, influencing how the Golimumab market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.

1

Embracing Biosimilars:

In the changing landscape of the pharmaceutical sectors development there seems to be a move away from conventional medications towards biosimilars, which are akin to biological medical products. Golimumab—a biologic for autoimmune conditions—has felt the effects of this change. The emergence of biosimilars like Simponi has intensified competition in the market and led to price reductions providings patients with better access, to treatments. Furthermore the increased profitability linked with biosimilars is attracting a number of companies to venture into this field. This surge is fostering advancements and effectiveness, in golimumab therapies.

2

Technological Innovation in Drug Administration:

The golimumab sector has also gone through a shift in how the drugs given to patients in the past compared to now – where patients used to go to healthcare facilities for their golimumab doses which was quite a hassle for them but thanks to advancements in the industry we now have self administered injectable drugs such, as Simponi that allow patients to receive treatment in the comfort of their homes whenever they want.

Global Events Shaping Future Growth

The chart below highlights how external events including emerging market developments, regulatory changes, and technological disruptions, have added another layer of complexity to the Pharmaceutical industry. These events have disrupted supply networks, changed consumption behavior, and reshaped growth patterns. Together with structural industry transitions, they demonstrate how changes within the Pharmaceutical industry cascade into the Golimumab market, setting the stage for its future growth trajectory.

Market Dynamics and Supply Chain

Driver: Rising Prevalence of Autoimmune Disorders, and Expansion of Healthcare Coverage

The prevalence of disorders like rheumatoid arthritis and psoriatic arthritis that golimumab effectively treats are also increasing worldwide nowadays. These conditions have also led to a demand for efficient treatments like golimumab which has also resulted in the growth of its market share. The significance of this drug in medical practices lies in its diverse applications, for treating autoimmune illnesses.
The rise in healthcare coverage means that more individuals can also now benefit from top notch healthcare services and medications in the market today like golimumab which is also gradually becoming more popular among patients due to its affordability compared to traditional treatments. This increased availability of golimumab opens up opportunities, for its market growth and expansion moving forward.
Progress in the field of biologics has also led to the development of treatments for different long term health conditions. Golimumab is also a biologic that has also seen enhancements due to these advancements making it more effective as a treatment option. Moreover the rise in research and development efforts focused on biologics could also open up avenues for growth, within the industry.

Restraint: Regulatory Hurdles

Treatment for conditions involves Golimumab which is a sophisticated drug that needs to go through strict regulatory processes for approval in various regions worldwide. This can be challenging due to the need to adhere to differing pharmaceutical regulations across countries. For example the strict criteria for conducting trials can lead to increased expenses and prolonged timelines. This delay in making the medication accessible, in the market may hinder its demand.

Challenge: Market Competition and Patent Cliff

In a market like golimumab operates in a competitive environment where various biologics and biosimilars are competing for market share. Once the patent for the medication expires the competition intensifies as more affordable alternatives become available impacting the market dynamics and demand, for golimumab and hindering its growth potential.

Supply Chain Landscape

Raw Material Procurement

Sanofi

Pfizer

API Production

Johnson & Johnson

AbbVie

Drug Formulation
Janssen Biotech / Mitsubishi Tanabe Pharma Corporation
Distribution
Hospitals / Rheumatology clinics / Pharmacies
Raw Material Procurement

Sanofi

Pfizer

API Production

Johnson & Johnson

AbbVie

Drug Formulation

Janssen Biotech

Mitsubishi Tanabe Pharma Corporation

Distribution

Hospitals

Rheumatology clinics

Pharmacies

Banner LogoBanner Logo

Leading Providers and Their Strategies

Application AreaIndustryLeading Providers / ConsumersProvider Strategies
Rheumatoid Arthritis
Pharmaceutical Industry
Janssen Biotech
Development of combination therapy using golimumab for enhanced treatment efficacy
Psoriatic Arthritis
Healthcare
Merck Sharp & Dohme
Leveraging advanced bioengineering techniques to improve golimumab delivery mechanisms
Ankylosing Spondylitis
Biotechnology
Janssen Pharmaceutica
Implementing innovation in drug formulation to maximize golimumab benefits
Ulcerative Colitis
Pharmaceuticals
Johnson & Johnson
Expanding the scope of golimumab into non-traditional markets to meet global demand

Elevate your strategic vision with in-depth analysis of key applications, leading market players, and their strategies. The report analyzes industry leaders' views and statements on the Golimumab market's present and future growth.

Our research is created following strict editorial standards. See our Editorial Policy

Applications of Golimumab in Ankylosing Spondylitis Therapy, Rheumatoid Arthritis Treatment and Psoriatic Arthritis Management

Ankylosing Spondylitis Therapy

The use of golimumab represents an advancement in the treatment of Ankylosing Spondylitis as healthcare providers frequently suggest intravenous golimumab due to its quick effectiveness and advantages, in managing this condition.

Rheumatoid Arthritis Treatment

Golimumab is a human monoclonal antibody Simponi. Plays a vital role in the treatment of Rheumatoid Arthritis by targeting tumor necrosis factor alpha . This substance contributes to inflammation and the development of symptoms associated with Rheumatoid Arthritis. Prominent pharmaceutical companies such, as Johnson & Johnson and Merck & Co are well known for utilizing the advantages of golimumab in the worldwide market.

Psoriatic Arthritis Management

From a perspective the use of golimumab is crucial in treating Psoriatic Arthritis. Subcutaneous administration of golimumab is the method in this context owing to its effectiveness and positive outcomes. The medication has demonstrated results in alleviating symptoms and slowing down the advancement of Psoriatic Arthritis. Significantly companies such as Johnson & Johnson have embraced this approach successfully strengthen their position, in the market space.

Golimumab vs. Substitutes:
Performance and Positioning Analysis

Golimumab surpasses its alternatives with greater bioavailability, resulting in increased effectiveness for autoimmune disorders. Its unique market positioning, with potential growth, is driven by patent exclusivity and the rising prevalence of such diseases

Golimumab
  • Adalimumab /
  • Infliximab /
  • Certolizumab Pegol
    Effective in reducing symptoms of autoimmune diseases, high specificity for TNF-alpha
    High cost, potential for serious side effects
    Efficacy in treating multiple autoimmune disorders, fewer side effects in comparison to other biologic agents
    Higher cost

Golimumab vs. Substitutes:
Performance and Positioning Analysis

Golimumab

  • Effective in reducing symptoms of autoimmune diseases, high specificity for TNF-alpha
  • High cost, potential for serious side effects

Adalimumab / Infliximab / Certolizumab Pegol

  • Efficacy in treating multiple autoimmune disorders, fewer side effects in comparison to other biologic agents
  • Higher cost

Golimumab surpasses its alternatives with greater bioavailability, resulting in increased effectiveness for autoimmune disorders. Its unique market positioning, with potential growth, is driven by patent exclusivity and the rising prevalence of such diseases

Loading...

Research Methodology

This market research methodology defines the Golimumab market scope, gathers reliable data, and validates findings using integrated primary and secondary research. Our systematic framework ensures precise market sizing, growth trend analysis, and competitive benchmarking.


Secondary Research Approach


We begin secondary research by defining the targeted market at Country and Regional levels. As part of the Pharmaceutical ecosystem, we analyze Golimumab across Hospitals & Clinics, Home Care, and Ambulatory Care Centers Applications. Our team gathers data systematically from country level ministerial sources, industry associations & federations, trade databases, company annual & quarterly reports and other credential sources, enabling us to map global and regional market size, pricing trends, regulatory standards, and technology advancements.


Key Sources Referenced:


We benchmark competitors such as Johnson & Johnson, Merck & Co. Inc, and Pfizer Inc by reviewing company financial statements, and regulatory filings. Our secondary insights identify key market drivers and constraints, forming the analytical foundation for primary research.


Primary Research Methods


We conduct structured interviews and surveys with industry stakeholders, including Raw Material Procurement, API Production, and Drug Formulation. Our geographic coverage spans Americas (40%), Europe (30%), Asia-Pacific (25%) and Middle East & Africa (5%). Our online surveys generally achieve a response rate of above 65%, and telephone interviews yield 60%, resulting in above 92% confidence level with a ±7% margin of error.


Through targeted questionnaires and in-depth interviews, we capture purchase intent, adoption barriers, brand perception across Segment Type. We use interview guides to ensure consistency and anonymous survey options to mitigate response bias. These primary insights validate secondary findings and align market sizing with real-world conditions.


Market Engineering & Data Analysis Framework


Our data analysis framework integrates Top-Down, Bottom-Up, and Company Market Share approaches to estimate and project market size with precision.


Top-down & Bottom-Up Process


In Top-down approach, we disaggregate global Pharmaceutical revenues to estimate the Golimumab segment, using historical growth patterns to set baseline trends. Simultaneously, in Bottom-up approach, we aggregate Country-Level Demand Data to derive regional and global forecasts, which provide granular consumption insights. By reconciling both approaches, we ensure statistical precision and cross-validation accuracy.


We evaluate the supply chain, spanning Raw Material Procurement (Sanofi, Pfizer), API Production (Johnson & Johnson, AbbVie), and Drug Formulation. Our parallel substitute analysis examines Adalimumab, Infliximab, and Certolizumab Pegol, highlighting diversification opportunities and competitive risks.


Company Market Share & Benchmarking


We benchmark leading companies such as Johnson & Johnson, Merck & Co. Inc, and Pfizer Inc, analyzing their capabilities in pricing, product features, technology adoption, and distribution reach. By assessing company-level revenues and product portfolios, we derive market share comparisons, clarifying competitive positioning and growth trajectories across the ecosystem.


Our integration of data triangulation, supply chain evaluation, and company benchmarking, supported by our proprietary Directional Superposition methodology enables us to deliver precise forecasts and actionable strategic insights into the Golimumab market.


Quality Assurance and Compliance


We cross-reference secondary data with primary inputs and external expert reviews to confirm consistency. Further, we use stratified sampling, anonymous surveys, third-party interviews, and time-based sampling to reduce bias and strengthen our results.


Our methodology is developed in alignment with ISO 20252 standards and ICC/ESOMAR guidelines for research ethics. The study methodology follows globally recognized frameworks such as ISO 20252 and ICC codes of practice.

rm

Golimumab Market Data: Size, Segmentation & Growth Forecast

Report AttributeDetails
Market Value in 2025USD 17.5 billion
Revenue Forecast in 2034USD 25.6 billion
Growth RateCAGR of 4.3% from 2025 to 2034
Base Year for Estimation2024
Industry Revenue 202416.8 billion
Growth OpportunityUSD 8.8 billion
Historical Data2019 - 2023
Growth Projection / Forecast Period2025 - 2034
Market Size UnitsMarket Revenue in USD billion and Industry Statistics
Market Size 202416.8 billion USD
Market Size 202719.1 billion USD
Market Size 202920.7 billion USD
Market Size 203021.6 billion USD
Market Size 203425.6 billion USD
Market Size 203526.7 billion USD
Report CoverageMarket revenue for past 5 years and forecast for future 10 years, Competitive Analysis & Company Market Share, Strategic Insights & trends
Segments CoveredDrug Form, Treatment Application, Distribution Channel, End-User
Regional scopeNorth America, Europe, Asia Pacific, Latin America and Middle East & Africa
Country scopeU.S., Canada, Mexico, UK, Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Mexico, Argentina, Saudi Arabia, UAE and South Africa
Companies ProfiledJohnson & Johnson, Merck & Co. Inc, Pfizer Inc, AbbVie Inc, Eli Lilly and Company, Amgen Inc, Bristol-Myers Squibb, Celltrion Inc, Gilead Sciences, Biocon Ltd, Momenta Pharmaceuticals and Mylan N.V.
CustomizationFree customization at segment, region or country scope and direct contact with report analyst team for 10 to 20 working hours for any additional niche requirement which is almost equivalent to 10% of report value

Explore Report Features and Data Packages

Industry Insight Report

$ 4200
Unlock Multi-User Access for just $999 more
i
No Payment Before Report Delivery
Flexible Payment Options
Additional Features
Customization Available
i
Excel Data Pack Included
Free Analyst Support
i
Industry Expert-Validated Insights
100% Confidentiality Guaranteed
Fast Delivery (24–72 hours)
i
Get Report Now

Strategic Growth Advisory

Unrivaled Custom Market Intelligence & Strategic Advisory for Business Growth and Competitive Excellence

  • Assess and prioritize high-value markets with precision
  • Craft tailored entry and expansion roadmaps
  • De-risk investments through rigorous market intelligence
  • Architect dynamic pricing frameworks aligned to value creation
  • Unlock sustainable margin enhancement opportunities
  • Benchmark performance against global industry leaders
  • Strategically realign portfolios to future growth drivers
  • Accelerate commercialization of breakthrough offerings
  • Harness market foresight and technology shifts to fuel innovation

Discover our Strategic Growth Advisory Services »

Table of Contents

Industry Insights Report - Table Of Contents

Chapter 1

Executive Summary

Major Markets & Their Performance - Statistical Snapshots

Chapter 2

Research Methodology

2.1Axioms & Postulates
2.2Market Introduction & Research MethodologyEstimation & Forecast Parameters / Major Databases & Sources
Chapter 3

Market Dynamics

3.1Market OverviewDrivers / Restraints / Opportunities / M4 Factors
3.2Market Trends
3.2.1Introduction & Narratives
3.2.2Market Trends - Impact Analysis(Short, Medium & Long Term Impacts)
3.3Supply Chain Analysis
3.4Porter's Five ForcesSuppliers & Buyers' Bargaining Power, Threat of Substitution & New Market Entrants, Competitive Rivalry
Chapter 4

Golimumab Market Size, Opportunities & Strategic Insights, by Drug Form

4.1Injection
4.2Infusion
Chapter 5

Golimumab Market Size, Opportunities & Strategic Insights, by Treatment Application

5.1Rheumatoid Arthritis
5.2Psoriatic Arthritis
5.3Ankylosing Spondylitis
5.4Others
Chapter 6

Golimumab Market Size, Opportunities & Strategic Insights, by Distribution Channel

6.1Retail Pharmacies
6.2Hospital Pharmacies
6.3Online Pharmacies
Chapter 7

Golimumab Market Size, Opportunities & Strategic Insights, by End-User

7.1Hospitals & Clinics
7.2Home Care
7.3Ambulatory Care Centers
7.4Others
Chapter 8

Golimumab Market, by Region

8.1North America Golimumab Market Size, Opportunities, Key Trends & Strategic Insights
8.1.1U.S.
8.1.2Canada
8.2Europe Golimumab Market Size, Opportunities, Key Trends & Strategic Insights
8.2.1Germany
8.2.2France
8.2.3UK
8.2.4Italy
8.2.5The Netherlands
8.2.6Rest of EU
8.3Asia Pacific Golimumab Market Size, Opportunities, Key Trends & Strategic Insights
8.3.1China
8.3.2Japan
8.3.3South Korea
8.3.4India
8.3.5Australia
8.3.6Thailand
8.3.7Rest of APAC
8.4Middle East & Africa Golimumab Market Size, Opportunities, Key Trends & Strategic Insights
8.4.1Saudi Arabia
8.4.2United Arab Emirates
8.4.3South Africa
8.4.4Rest of MEA
8.5Latin America Golimumab Market Size, Opportunities, Key Trends & Strategic Insights
8.5.1Brazil
8.5.2Mexico
8.5.3Rest of LA
8.6CIS Golimumab Market Size, Opportunities, Key Trends & Strategic Insights
8.6.1Russia
8.6.2Rest of CIS
Chapter 9

Competitive Landscape

9.1Competitive Dashboard & Market Share Analysis
9.2Company Profiles (Overview, Financials, Developments, SWOT)
9.2.1Johnson & Johnson
9.2.2Merck & Co. Inc
9.2.3Pfizer Inc
9.2.4AbbVie Inc
9.2.5Eli Lilly and Company
9.2.6Amgen Inc
9.2.7Bristol-Myers Squibb
9.2.8Celltrion Inc
9.2.9Gilead Sciences
9.2.10Biocon Ltd
9.2.11Momenta Pharmaceuticals
9.2.12Mylan N.V.